Wall Street brokerages forecast that InVitae Corp (NYSE:NVTA) will post sales of $68.78 million for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for InVitae’s earnings, with the lowest sales estimate coming in at $65.60 million and the highest estimate coming in at $70.78 million. InVitae posted sales of $45.36 million during the same quarter last year, which would indicate a positive year over year growth rate of 51.6%. The business is expected to announce its next earnings report after the market closes on Wednesday, February 19th.
On average, analysts expect that InVitae will report full-year sales of $216.20 million for the current financial year. For the next year, analysts anticipate that the company will report sales of $319.57 million, with estimates ranging from $307.27 million to $333.00 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow InVitae.
NVTA has been the topic of a number of research analyst reports. ValuEngine lowered InVitae from a “buy” rating to a “hold” rating in a report on Tuesday, January 14th. Zacks Investment Research lowered InVitae from a “hold” rating to a “sell” rating in a report on Thursday, January 16th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. InVitae has an average rating of “Buy” and an average price target of $27.83.
NYSE NVTA traded up $0.79 on Friday, reaching $27.04. The company had a trading volume of 3,429,900 shares, compared to its average volume of 3,046,787. InVitae has a 1 year low of $14.35 and a 1 year high of $28.75. The company has a debt-to-equity ratio of 0.77, a current ratio of 7.38 and a quick ratio of 7.38. The firm has a 50-day moving average of $19.04 and a 200-day moving average of $19.93. The firm has a market capitalization of $2.53 billion, a PE ratio of -12.13 and a beta of 2.43.
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders.
Featured Story: 52-Week High/Low Prices For Stock Selection
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.